

Massimo Levrero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4778796/publications.pdf>

Version: 2024-02-01

47
papers

7,387
citations

136950

32
h-index

243625

44
g-index

48
all docs

48
docs citations

48
times ranked

7164
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. <i>Nature</i> , 1999, 399, 806-809. | 27.8 | 863 |
| 2 | Mechanisms of HBV-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, S84-S101. | 3.7 | 664 |
| 3 | IFN- γ inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. <i>Journal of Clinical Investigation</i> , 2012, 122, 529-537. | 8.2 | 492 |
| 4 | Control of cccDNA function in hepatitis B virus infection. <i>Journal of Hepatology</i> , 2009, 51, 581-592. | 3.7 | 476 |
| 5 | Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19975-19979. | 7.1 | 403 |
| 6 | Hepatitis B Virus Replication Is Regulated by the Acetylation Status of Hepatitis B Virus cccDNA-Bound H3 and H4 Histones. <i>Gastroenterology</i> , 2006, 130, 823-837. | 1.3 | 401 |
| 7 | Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. <i>Journal of Hepatology</i> , 2011, 55, 996-1003. | 3.7 | 361 |
| 8 | A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558. | 8.1 | 342 |
| 9 | Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408. | 3.7 | 341 |
| 10 | Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. <i>Nature Medicine</i> , 2017, 23, 327-336. | 30.7 | 251 |
| 11 | Differential regulation of E2F1 apoptotic target genes in response to DNA damage. <i>Nature Cell Biology</i> , 2003, 5, 552-558. | 10.3 | 249 |
| 12 | Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015, 64, 1314-1326. | 12.1 | 234 |
| 13 | Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 615-625. | 3.7 | 204 |
| 14 | Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, 897-909. | 3.7 | 125 |
| 15 | Control of hepatitis B virus replication by innate response of HepaRG cells. <i>Hepatology</i> , 2010, 51, 63-72. | 7.3 | 124 |
| 16 | PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. <i>Hepatology</i> , 2017, 66, 398-415. | 7.3 | 101 |
| 17 | Molecular Mechanisms of HBV-Associated Hepatocarcinogenesis. <i>Seminars in Liver Disease</i> , 2013, 33, 147-156. | 3.6 | 96 |
| 18 | Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription. <i>Gut</i> , 2020, 69, 2016-2024. | 12.1 | 92 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Current treatments for chronic hepatitis B virus infections. <i>Current Opinion in Virology</i> , 2016, 18, 109-116. | 5.4 | 70 |
| 20 | Structural Variations of Vaginal and Endometrial Microbiota: Hints on Female Infertility. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 350. | 3.9 | 67 |
| 21 | IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome. <i>PLoS ONE</i> , 2015, 10, e0142599. | 2.5 | 66 |
| 22 | Aiming for cure in HBV and HDV infection. <i>Journal of Hepatology</i> , 2016, 65, 835-848. | 3.7 | 66 |
| 23 | Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. <i>Liver International</i> , 2017, 37, 1122-1127. | 3.9 | 60 |
| 24 | HCV core-mediated activation of latent TGF- β 2 via thrombospondin drives the crosstalk between hepatocytes and stromal environment. <i>Journal of Hepatology</i> , 2013, 59, 1160-1168. | 3.7 | 53 |
| 25 | Genome-wide identification of direct HBx genomic targets. <i>BMC Genomics</i> , 2017, 18, 184. | 2.8 | 52 |
| 26 | HBV cure: why, how, when?. <i>Current Opinion in Virology</i> , 2016, 18, 135-143. | 5.4 | 50 |
| 27 | Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. <i>Current Opinion in Virology</i> , 2018, 30, 80-89. | 5.4 | 44 |
| 28 | Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation. <i>Hepatology</i> , 1999, 30, 510-516. | 7.3 | 40 |
| 29 | p53 and p73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy. <i>FEBS Letters</i> , 2014, 588, 2590-2599. | 2.8 | 39 |
| 30 | Non-invasive biomarkers for chronic hepatitis B virus infection management. <i>Antiviral Research</i> , 2019, 169, 104553. | 4.1 | 38 |
| 31 | Binding of CDK9 to TRAF2. <i>Journal of Cellular Biochemistry</i> , 1998, 71, 467-478. | 2.6 | 34 |
| 32 | Challenges to a Cure for HBV Infection. <i>Seminars in Liver Disease</i> , 2017, 37, 231-242. | 3.6 | 31 |
| 33 | Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma. <i>Viruses</i> , 2018, 10, 591. | 3.3 | 30 |
| 34 | Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus. <i>Hepatology</i> , 2021, 73, 861-864. | 7.3 | 26 |
| 35 | Hepatitis Delta Virus histone mimicry drives the recruitment of chromatin remodelers for viral RNA replication. <i>Nature Communications</i> , 2020, 11, 419. | 12.8 | 19 |
| 36 | Ribavirin restores IFN- α responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. <i>Gut</i> , 2016, 65, 672-682. | 12.1 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Performance of the cobas® HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105150. | 3.1 | 14 |
| 38 | Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 1715. | 2.4 | 12 |
| 39 | A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro. <i>Viruses</i> , 2020, 12, 251. | 3.3 | 8 |
| 40 | Downregulation of miR-326 and its host gene <i>p21</i> induces pro-survival activity of E2F1 and promotes medulloblastoma growth. <i>Molecular Oncology</i> , 2021, 15, 523-542. | 4.6 | 8 |
| 41 | The lncRNAs in HBV-Related HCCs: Targeting Chromatin Dynamics and Beyond. <i>Cancers</i> , 2021, 13, 3115. | 3.7 | 6 |
| 42 | Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells. <i>Journal of Visualized Experiments</i> , 2019, , . | 0.3 | 3 |
| 43 | External validation of the French alpha-fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort – a retrospective study. <i>Transplant International</i> , 2021, 34, 535-545. | 1.6 | 2 |
| 44 | DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. , 0, . | | 2 |
| 45 | Arsenic Trioxide (ATO) and MEK1 Inhibitor Activate Apoptotic p73 Pathway in Primary Acute Myelogenous Leukemia Blasts.. <i>Blood</i> , 2005, 106, 613-613. | 1.4 | 0 |
| 46 | Combined Treatment with the Mek Inhibitor PD0325901 and Arsenic Trioxide Has Potent Antitumor Activity in Vivo against Human Multiple Myeloma Xenograft Model.. <i>Blood</i> , 2008, 112, 1712-1712. | 1.4 | 0 |
| 47 | Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Myeloma Cells Sensitive and Resistant to Bortezomib.. <i>Blood</i> , 2009, 114, 1837-1837. | 1.4 | 0 |